China Omarigliptin (MK-3102; MK3102) CAS 1226781-44-7,Omarigliptin (MK-3102; MK3102) CAS 1226781-44-7 Manufacturer Sign in | Join Now | Sitemap | Inquiry Basket(0)
customer feedback | Message
Products Show
Home > API > Omarigliptin (MK-3102; MK3102) CAS 1226781-44-7

Omarigliptin (MK-3102; MK3102) CAS 1226781-44-7

  • Product Name:  Omarigliptin (MK-3102; MK3102) CAS 1226781-44-7
  • Model NO.:  1226781-44-7
  • Origin:  China
  • Packing:  25KG/Drum
  • Brand Name:  Volsen
Product Details:  Omarigliptin (MK-3102; MK3102) CAS 1226781-44-7

Backed by a team of professional, we we manufacture, export and supply high quality Omarigliptin CAS 1226781-44-7. Omarigliptin CAS 1226781-44-7 is a panacea for some patient who suffer from Type 2 Diabetes. Omarigliptin CAS 1226781-44-7 is high purity, superior quality, fast action that are appreciated by many customers. Our aim is to offer more high quality product to customers from all the world. We own largest production base and professional staffs to ensure the inventory. We have ability to offer bulk needs for the customers.

Thera. Category:Antidiabetic

Cas No.: 1226781-44-7

Synonyms: MK-3102;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(Methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-aMine;MK-3012;(2S,3R,5S)-2-(2,5-Difluorophenyl)-5-[2-(Methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-aMine (MK-3102 enantioMer);(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine;OMarigliptin;OMarigliptin (MK-3102);2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine MK3102

Molecular Formula: C17H20F2N4O3S

Molecular Weight: 398.43


Assay: ≥99%

Packing: Export worthy packing

Material Safety Data Sheet: Available on request


Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co.[1] It inhibits DPP-4 to increase incretin levels (GLP-1 and GIP),[2][3][4] which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.

Share to:
Home | Product Show Room | Download | News | Company Profile | Contact Us | Sitemap | Link| Privacy Policy
Copyright © Taizhou Volsen Chemical Co., Ltd. All rights reserved..
Internet Marketing By Netcec& Bossgoo